🇪🇺 Fast delivery (3–5 working days) with GLS ✅ Bank transfer in advance 📦 Free shipping from €50
Peptides for weight loss




Retatrutide 5mg/10mg/15mg/30mg - Triple agonist (GLP-1/GIP/GCGR) — 59,00 €
Tirzepatide 5 mg/10mg/15mg/30mg – Dual agonist (GLP-1/GIP) — 59,00 €
Semaglutide 5 mg/10mg – GLP-1 receptor agonist — 50,00 €
Cagrilintide 5 mg/10 mg – Amylin analogue — 45,00 €
CS10 (Cagrilintide 5 mg + Semaglutide 5 mg) – Dual GLP-1 / Amylin agonist — 75,00 €
CS20 (Cagrilintide 10 mg + Semaglutide 10 mg) — dual GLP-1 / amylin agonist — 119,00 €
Eloralintide 10 mg – Selective amylin receptor agonist — 125,00 €The Peptology category “Peptides for weight loss” brings together molecules that act on appetite regulation and energy metabolism through three different mechanisms: the incretin pathway (GLP-1 and GIP), the glucagon pathway and the amylin pathway. The difference between the products is not their “strength” but how many receptors they activate — and which ones.
All products ship with GLS in 3–5 working days — lyophilised, with confirmed purity above 99% (HPLC/MS) and an independent laboratory certificate (CoA) for every batch.
THE INCRETIN PATHWAY
GLP-1 is the hormone the gut releases after a meal. Its agonists slow gastric emptying and act on the hypothalamic satiety centres. GIP is the second incretin, with a role in lipid handling.
THE GLUCAGON PATHWAY
The glucagon receptor works on the other side of the energy balance — not on intake but on expenditure. It is the only pathway in the category that raises energy expenditure rather than only lowering appetite.
THE AMYLIN PATHWAY
Amylin is secreted alongside insulin by the beta cells and acts through its own receptors, entirely separate from the incretin receptors. That is why it combines logically with a GLP-1 agonist.
Three products cover most of the scenarios being studied — one for each level of mechanistic complexity.
The triple agonist. GLP-1, GIP and glucagon in a single molecule. Published phase-2 data report an average body-weight reduction of about 24% and a drop in liver fat of over 80%, with a half-life of roughly 6 days.
The dual GIP/GLP-1 agonist. The first molecule of the class to activate two incretin receptors at once. Average weight reduction of about 22.5% in published studies — the balance between a strong effect and a well-documented profile.
CS10 (CAGRILINTIDE + SEMAGLUTIDE)
Two independent pathways in one vial. 5 mg cagrilintide and 5 mg semaglutide — amylin plus incretin. The CS20 variant contains 10 + 10 mg in the same ratio.
Semaglutide, tirzepatide and retatrutide are not variants of the same molecule but three levels of complexity. Each generation adds one more receptor pathway.
| Feature | Retatrutide | Tirzepatide | Semaglutide |
|---|---|---|---|
| Receptors activated | GLP-1 + GIP + glucagon | GLP-1 + GIP | GLP-1 |
| Weight reduction in studies | ≈ 24% | ≈ 22.5% | ≈ 16% |
| Energy expenditure | Directly increased | Indirectly affected | Indirectly affected |
| Liver fat | Reduction over 80% | Marked reduction | Moderate reduction |
| Typical choice for | The broadest metabolic model | A strong effect with a known profile | The GLP-1 reference model |
≈ 24%
RETATRUTIDE, PHASE 2
≈ 22.5%
TIRZEPATIDE
≈ 16%
SEMAGLUTIDE
99%+
PURITY WITH CoA
The rule is simple: you combine molecules that act on different receptors. Two molecules binding the same receptor do not add up — they compete.
AMYLIN + INCRETIN
Cagrilintide + semaglutide — two completely separate receptor systems. That is exactly the composition of CS10 and CS20.
READY-MADE OR SEPARATE
The same two molecules can also be used from separate vials when the model calls for a ratio other than 1:1, or for introducing one of them gradually.
+ SOLVENT
Every peptide needs a suitable reconstitution medium. See the Solutions for peptides category.
Conversely — semaglutide together with tirzepatide or retatrutide — adds no information: all three bind the GLP-1 receptor and compete for it. The same applies to CS10 together with separate semaglutide — the GLP-1 component is already in the vial.
In lyophilised form the products are stable at controlled room temperature (20–25 °C), protected from direct light and moisture. After reconstitution every peptide in this category is kept refrigerated.
Important notice: The products in this category are intended exclusively for laboratory research and scientific in-vitro analysis. They are not medicines, not approved preparations and not suitable for use in humans or animals. The mechanisms described come from the published scientific literature and constitute neither a promise of effect, nor a recommendation for use, nor a claim about the action of the research-grade products offered. A general comparison of the whole class is given in GLP-1 agonists: the new benchmarks.